GH Research (GHRS) Total Non-Current Liabilities (2023 - 2025)
GH Research's (GHRS) quarterly Total Non-Current Liabilities came in at $147000.0 in Q4 2025, down 60.16% year-on-year from $369000.0 in Q4 2024, and down 32.26% quarter-over-quarter from $217000.0 in Q3 2025.
GH Research (GHRS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
GH Research's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $147000.0 for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 60.16% year-over-year to $147000.0 in Q4 2025; TTM through Dec 2025 was $147000.0, a 60.16% decrease from a year earlier, with the FY2025 full-year figure at $147000.0, down 60.16% from the prior year.
- Total Non-Current Liabilities declined to $147000.0 in Q4 2025 per GHRS's latest filing, from $217000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $791000.0 in Q1 2023 and bottomed at $147000.0 in Q4 2025.
- The 3-year median for Total Non-Current Liabilities is $477500.0 (2024), against an average of $472416.7.
- Across the five-year window, Total Non-Current Liabilities slipped 29.08% in 2024 and tumbled 60.16% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $631000.0 in 2023, then plunged by 41.52% to $369000.0 in 2024, then sank by 60.16% to $147000.0 in 2025.
- Per Business Quant, the three latest GHRS Total Non-Current Liabilities figures stand at $147000.0 (Q4 2025), $217000.0 (Q3 2025), and $283000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147,000.00 |
| Sep 30, 2025 | 217,000.00 |
| Jun 30, 2025 | 283,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 497,000.00 |
| Mar 31, 2024 | 561,000.00 |
| Dec 31, 2023 | 631,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 732,000.00 |
| Mar 31, 2023 | 791,000.00 |